Palliative surgery plus earlier therapy versus chemotherapy for metastatic stomach cancer
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares two approaches for metastatic (spread to distant organs) stomach cancer: palliative surgery after a prior “translational” treatment versus ongoing maintenance chemotherapy. It aims to see which approach leads to better overall outcomes and symptom control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old
- Have stomach cancer confirmed by pathology, with a type listed by the trial (such as signet ring or poorly differentiated)
- Have scans (CT/MRI/PET-CT) or a procedure (laparoscopy) done before surgery that confirm distant spread
- Be able to do daily activities with limited symptoms (ECOG performance status 0 or 1) and expected survival > 3 months
- Your blood and organ tests must be within set safety ranges (including no blood transfusion within 14 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if surgery to remove the stomach and some tumors, after a few months of chemo, helps people whose stomach cancer has spread to only a few nearby spots (like the lining of the belly, liver, or lymph nodes) live longer compared to chemo alone.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial is for people with advanced stomach cancer that has shrunk after initial chemotherapy or targeted therapy. It compares whether adding surgery to continued medical treatment is better than staying on medical treatment alone, with the goal of improving outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding two drugs (mecapegfilgrastim and adebrelimab) to standard chemotherapy before surgery can help treat advanced stomach or gastroesophageal junction cancer that has not yet spread. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
Hear when a new Metastatic Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.